Carrageenan-based gel retains limited anti-HIV-1 activity 8-24 hours after vaginal application by HIV-infected Thai women enrolled in a phase I safety trial

J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):e71-3. doi: 10.1097/QAI.0b013e318271c8f9.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Letter
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Intravaginal
  • Anti-HIV Agents / administration & dosage*
  • Carrageenan / administration & dosage
  • Cross-Over Studies
  • Female
  • Gels
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1* / drug effects
  • HIV-1* / isolation & purification
  • Humans
  • Thailand
  • Therapeutic Irrigation
  • Time Factors
  • Vagina / drug effects
  • Vagina / virology
  • Viral Load / drug effects

Substances

  • Anti-HIV Agents
  • Gels
  • Carrageenan